ClinicalTrialsFinder

Secondary Hyperparathyroidism (SHPT) Clinical Trials in Hangzhou, Zhejiang

1 recruitingHangzhou, Zhejiang, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Shaanxi Micot Pharmaceutical Technology Co., Ltd.310 enrolled1 locationNCT06976177